Highest-materiality recent filing
SELLAS amends CEO Stergiou's COC severance to lump sum; revises Burns, Cicic agreements
CEO Stergiou's change-in-control severance: lump sum of 24 months base salary plus 1.5x target bonus, full equity vesting, 18-month COBRA.
SELLAS stockholders approve 20M share equity plan increase, re-elect directors
Directors Robert Van Nostrand and Jane Wasman re-elected; Van Nostrand 66.5M for, Wasman 65.9M for.
SELLAS Life Sciences raised $28.7M from warrant exercises in Apr-May 2026
Received approximately $28.7 million in proceeds from warrant exercises during April and May 2026.
SELLAS reports 78 events in REGAL AML trial; Q1 net loss $8.4M, cash $107.1M
78 events (deaths) occurred in pivotal Phase 3 REGAL trial of GPS in AML as of May 11; final analysis triggered at 80th event.
FY2025 net loss $26.9M ($0.25/shr) vs $30.9M ($0.50/shr) in FY2024; cash $71.8M at Dec 31, 2025.
SELLAS Life Sciences receives additional $16.1M from warrant exercises, total $42.6M since Dec 31
Additional $16.1M in proceeds from warrant exercises since January 8, 2026.
Cash and cash equivalents estimate of $71.8M as of Dec 31, 2025 (unaudited, preliminary).
SELLAS Q3 net loss $6.8M ($0.06/sh); cash $44.3M plus $29.1M warrant proceeds in Oct
Net loss of $6.8M ($0.06 diluted EPS) vs $7.1M ($0.10) a year ago; nine-month loss $19.2M ($0.20).
SELLAS receives $31M from warrant exercise; issues new warrants at $2 strike
Existing warrants for up to 22,363,714 shares exercised immediately for $31M gross proceeds.
SELLAS extends NYC office sublease by one year to Sept 2027 with no rent change
Sublease at Times Square Tower extended to September 30, 2027, from September 30, 2026.
SELLAS raises $23.6M via warrant exercise; issues new 5.5-yr warrants at $1.88 strike
Existing warrant holder cash exercises 19,685,040 shares at $1.20, yielding $23.6M gross proceeds.
SELLAS Q2 net loss $0.07/sh; GPS Phase 3 IDMC positive; SLS009 meets endpoints
IDMC recommends continuing pivotal Phase 3 REGAL trial of GPS in AML without modification; final analysis by year-end 2025.
SELLAS annual meeting results: directors re-elected, ESPP amendment approved
Re-elected Class III directors Stergiou (36.4M for) and Varian (36.7M for); broker non-votes 17.8M.
SELLAS appoints Baker Tilly as new auditor after Moss Adams merger
Moss Adams merged into Baker Tilly US, LLP; auditors resigned June 3, 2025.
SELLAS Q1 net loss $5.8M; cash $28.4M; reports positive OS in Phase 2 SLS009 AML trial
Net loss of $5.8M ($0.07 per share) for Q1 2025 vs $9.6M ($0.21) in Q1 2024.
SELLAS reports FY2024 net loss $30.9M; Phase 3 REGAL trial interim analysis positive
Net loss $30.9M ($0.50/share) vs $37.3M ($1.34) in FY2023; R&D expenses down to $19.1M.
SELLAS Life Sciences raises $25M in registered direct offering of common stock and warrants
19,685,040 shares (or pre-funded warrants) plus 19,685,040 common warrants at $1.27 combined price.
IDMC recommended continuation of Phase 3 REGAL trial after interim analysis triggered by 60 deaths; no safety concerns.
Board approved amendments to change-in-control severance agreements for SVP/Chief Development Officer Dragan Cicic and SVP/CFO John Burns.
SELLAS triggers interim analysis in Phase 3 REGAL trial of GPS in AML; IDMC meeting in Jan 2025
Pre-specified threshold of 60 deaths reached, triggering IDMC interim analysis.
SELLAS Q3 net loss narrows to $7.1M; Phase 3 AML interim analysis on track for Q4 2024
Q3 net loss $7.1M ($0.10/sh) vs $9.3M ($0.33/sh) in Q3 2023; cash $21M.
SELLAS extends NY office sublease by one year to Sept 2026; rent unchanged
Sublease expiration moved from Sept 30, 2025 to Sept 30, 2026.
SELLAS Life Sciences Q2 2024 net loss $7.5M; cash $9.1M; $21M capital raise; IDMC supports REGAL
Net loss $7.5M ($0.13/share) vs $8.8M ($0.31/share) in Q2 2023; R&D expenses $5.2M.
SELLAS Life Sciences raises $21M in registered direct offering at premium to market
Gross proceeds of ~$21M from sale of 15,849,056 units (share or pre-funded warrant + warrant) at $1.325/unit.
Scheinberg and Kalin re-elected as Class II directors (8.6M/8.8M for; 18.7M broker non-votes).
SELLAS Q1 net loss $9.6M; Phase 2 SLS009 100% response in ASXL1 AML; IDMC backs REGAL trial
Net loss of $9.6M ($0.21/share) vs $11.1M ($0.47/share) in Q1 2023.
GenFleet entered clinical trial collaboration with BeiGene for GFH009 (CDK9 inhibitor) and BRUKINSA (zanubrutinib).
SELLAS FY2023 net loss $37.3M; SLS009 shows 50% response rate in r/r AML
Net loss $37.3M ($1.34/sh) vs. $41.3M ($2.13/sh) in 2022; R&D expense $24.0M.
SELLAS raises ~$20M in registered direct offering plus warrants priced at $1.535/share
Gross proceeds of ~$20M from sale of 13,029,316 shares (or pre-funded warrants) at $1.535/share on Nasdaq.
SELLAS regains Nasdaq minimum bid price compliance effective March 11, 2024
Nasdaq confirmed compliance after closing bid price above $1.00 for 10 consecutive business days through March 8, 2024.
SELLAS terminates EVP General Counsel and SVP Chief Commercial Officer; reorganizes leadership
Barbara Wood (EVP, GC, Corp Secretary) terminated without cause, effective April 15, 2024.
SELLAS Life Sciences regains Nasdaq compliance for minimum market value rule
Received Nasdaq letter on March 5, 2024 confirming compliance with Listing Rule 5550(b)(2).
SELLAS receives Nasdaq deficiency notice for bid price below $1.00; has 180 days to cure
Nasdaq notified SELLAS on Feb 14, 2024 that common stock failed to maintain minimum $1.00 bid price for 30 consecutive business days.
SELLAS Life Sciences prices $9.0M public offering of 12M shares and warrants at $0.75/unit
Gross proceeds of $9.0M from sale of 12M shares/common stock equivalents and 12M warrants at $0.75 per unit.
SELLAS Life Sciences terminates $50M ATM sales agreement with Cantor Fitzgerald
Mutual termination of Controlled Equity Offering Sales Agreement dated April 16, 2021.
Dispute over $13M development milestone payments due under 2020 license agreement for GPS in China region.
SELLAS extends NYC office sublease term to Sept 2025; annual rent $635K from Jan 2025
Second Amendment to Sublease extends term from Dec 30, 2024 to Sep 30, 2025.
SELLAS receives Nasdaq deficiency notice for market value below $35M minimum
Nasdaq notified SLS on Dec 6, 2023 that MV of common stock was below $35M for 30 consecutive business days.
SELLAS Q3 net loss $9.3M; GPS Phase 3 enrollment complete, SLS009 shows CR in AML
Net loss $9.3M ($0.33/share) vs $7.0M in Q3 2022; cash $4.0M as of Sep 30, 2023; subsequent $4.0M offering.
SELLAS receives FDA Fast Track for SLS009 in PTCL; raises $4M via registered direct offering
FDA granted Fast Track Designation for SLS009 to treat relapsed/refractory Peripheral T-cell Lymphomas (PTCL).
First of 5 enrolled r/r AML patients achieved complete response, remains alive in 5th month of treatment.
SELLAS expects REGAL enrollment ex-China by Nov 2023; China start triggers $13M milestone
Enrollment outside China expected to complete in November 2023; patient numbers for interim and final analyses already enrolled.
SELLAS reports Q2 net loss $8.8M; AML trials on track with IDMC meeting Q3 2023
Net loss $8.8M ($0.31/share) vs $8.4M ($0.41/share) in Q2 2022; cash $13.8M at June 30.
Robert Van Nostrand and Jane Wasman re-elected as Class I directors with ~5.45M and ~5.48M votes for, respectively.
Phase 2a single-arm trial to enroll up to 20 R/R AML patients previously failed venetoclax/azacitidine; primary endpoints: composite CR rate, duration of response, safety.
SELLAS reports Q1 net loss $11.1M; GFH009 Phase 1 complete in AML, Phase 2a to start
Net loss $11.1M ($0.47/share) vs $16.7M ($1.05/share) in Q1 2022; cash $23.9M at March 31.
Net loss $41.3M ($2.13 per share) vs $20.7M loss ($1.34 per share) in 2021.
SELLAS says exposure to Silicon Valley Bank closure is immaterial
SVB closed by California regulator; FDIC appointed receiver.
SELLAS closes $18.5M offering; reprices 3.4M warrants to $3.62
Closed underwritten offering of 7,220,217 shares and warrants for net proceeds of ~$18.5M.
SELLAS Life Sciences prices $20M public offering of common stock and warrants
7,220,217 shares and warrants at $2.77/unit; gross proceeds $20M.
In addition, on March 6, 2024, Robert Francomano, Senior Vice President and Chief Commercial Officer of the Company, was terminated without cause, effective March 31, 2024.
On March 6, 2024, Barbara A. Wood, Executive Vice President, General Counsel and Corporate Secretary of SELLAS Life Sciences Group, Inc. (the “Company”), was terminated without cause, effective April 15, 2024.
On February 2, 2023, the Board of Directors (the “BOD”) of the Company appointed John T. Burns, the Company’s Senior Vice President, Finance and Chief Accounting Officer, as the Company’s Chief Financial Officer and principal financial officer.
On August 13, 2022, the Board of Directors (the “Board”) of SELLAS Life Sciences Group, Inc. (the “Company”) elected Katherine Bach Kalin as a member of the Board, effective immediately, to serve as a Class II director until the Company’s 2024 annual meeting of stockholders and thereafter until her successor is duly elected and qualified or until her earlier death, resignation or removal.
Max materiality 0.85 · Median 0.65 · Most common event other_material